A Phase III trial of RP-G28.

Trial Profile

A Phase III trial of RP-G28.

Planning
Phase of Trial: Phase III

Latest Information Update: 02 May 2017

At a glance

  • Drugs RP G28 (Primary)
  • Indications Lactose intolerance
  • Focus Registrational; Therapeutic Use
  • Sponsors Ritter Pharmaceuticals
  • Most Recent Events

    • 02 May 2017 According to a Ritter Pharmaceuticals media release, the company is planning an end of phase 2 meeting with the FDA to present and discuss the plan of this trial. This trial will support NDA submission. The company will discuss the final features of this trial with the FDA at upcoming meeting.
    • 12 Apr 2017 According to a Ritter Pharmaceuticals media release, the company anticipates the initiation of the trial in the first half of 2018 and plans in preparation of a New Drug Application (NDA) submission of RP-G28 for the treatment of lactose intolerance.
    • 01 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top